Company: FTII
Filing Date: 2025-04-09
Form Type: 10-K
Source: 0001641172-25-003384
Chunk: 395

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-04-09
Form: 10-K
Item: Item 8
Chunk 395
---
, 2022, between the Company and Continental Stock Transfer & Trust Company. (2)
  
    4.5
     
    Description of Registered Securities.*
  
    10.1
     
    Letter Agreement, dated February 16, 2022, among the Company, its officers and directors and the Company’s sponsor, FutureTech Partners II LLC. (2)
  
    10.2
     
    Promissory Note, dated August 19, 2021, issued by the Company (1)
  
    10.3
     
    Investment Management Trust Agreement, dated February 18, 2022 between the Company and Continental Stock Transfer & Trust Company. (2)
  
    10.4
     
    Registration Rights Agreement, dated February 18, 2022, by and among the Company and certain securityholders. (2)
  
    10.5
     
    Administrative Support Agreement, dated February 18, 2022, by and between the Company and FutureTech Partners II LLC. (2)
  
    10.6
     
    Placement Unit Purchase Agreement, dated February 18, 2022, by and between the Company and the Sponsor. (2)
  
    10.7
     
    Form of Indemnity Agreement. (2)
  
    10.8
     
    Securities Subscription Agreement, dated October 8, 2021, by and between the Registrant and FutureTech Partners II LLC. (1)
  
    10.9
     
    Amendment to the Investment Management Trust Agreement, dated February 18, 2022 between the Company and Continental Stock Transfer & Trust Company. (3)

    10.11
     
    Voting and Support Agreement, dated September 16, 2024 by and among Longevity Biomedical, Inc., FutureTech II Acquisition Corp., and FutureTech Partners II LLC (incorporated by reference to Exhibit 10.1 to the Company’s Form 8-K (File No. 001-41289), filed with the SEC on September 20, 2024)
  
    10.12
     
    Company Voting and Support Agreement, dated September 16, 2024, by and among Longevity Biomedical, Inc., FutureTech II Acquisition Corp. and the sole securityholder of Longevity (incorporated by reference to Exhibit 10.2 to the Company’s Form 8